ASTEROGENE Biomedical

Asterogene is a clinical-stage biotechnology company dedicated to developing transformative gene therapies for ophthalmic and neurological disorders. The company utilizes its proprietary adeno-associated virus (AAV) vector platform to create treatments for inherited retinal diseases with high unmet medical needs. Its lead candidate, AST-101, is currently in clinical development for the treatment of RPE65-related Leber congenital amaurosis and retinitis pigmentosa. Beyond ophthalmology, Asterogene is expanding its research into neurological conditions, leveraging its expertise in genetic medicine. Headquartered in Suzhou, China, the company is backed by prominent venture capital firms and led by a team of industry veterans.